Zimmer Biomet (ZBH) and OneStep announced an exclusive collaboration agreement aimed at delivering the orthopedic industry’s most comprehensive set of mobility data to further empower surgeons to track recovery progress more effectively following joint replacement surgery and enable patients to play an active role in their recovery. The collaboration will use OneStep’s gait and mobility analytics that are captured on both iPhone and Android smartphones and integrate the data directly into Zimmer Biomet’s mymobility Care Management Platform for orthopedic surgery patients. Users of mymobility have access to daily, objective insights across their joint replacement journey, from surgical preparation through recovery using only their smartphone. The integration enables remote assessment of gait and functional mobility powered by OneStep’s clinically validated technology, delivered seamlessly through the mymobility app.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet downgraded to Neutral from Outperform at Baird
- Zimmer Biomet price target lowered to $94 from $98 at Citi
- Zimmer Biomet announces FDA clearance of ROSA Knee with OptimiZe
- Zimmer Biomet price target lowered to $93 from $101 at Canaccord
- Zimmer Biomet price target lowered to $88 from $96 at UBS